Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
$13.41
-0.7%
$12.73
$7.90
$19.09
$1.79B1.53661,194 shs770,363 shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$21.22
+6.7%
$17.78
$13.45
$44.42
$1.86B0.261.02 million shs1.86 million shs
Pfenex Inc. stock logo
PFNX
Pfenex
$12.75
$12.75
$5.26
$14.00
$437.29MN/A503,865 shsN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$31.07
+6.0%
$35.28
$27.12
$60.90
$1.86B2.54984,618 shs1.91 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
0.00%+2.10%-3.45%-12.63%+52.26%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
0.00%+6.54%-4.20%+4.81%-45.14%
Pfenex Inc. stock logo
PFNX
Pfenex
0.00%0.00%0.00%0.00%0.00%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
0.00%+4.46%-24.77%-20.45%-29.55%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
3.4398 of 5 stars
4.51.00.00.03.23.30.6
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
3.9099 of 5 stars
3.52.00.04.43.51.70.0
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
4.3299 of 5 stars
4.41.00.04.44.20.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
3.00
Buy$27.89107.97% Upside
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.93
Moderate Buy$54.27155.76% Upside
Pfenex Inc. stock logo
PFNX
Pfenex
0.00
N/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4062.21% Upside

Current Analyst Ratings Breakdown

Latest PFNX, CNTA, IDYA, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$35.00
5/22/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.00
5/8/2025
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform ➝ Outperform$6.00
5/8/2025
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
4/10/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$58.00 ➝ $45.00
3/31/2025
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$38.00
3/28/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
$15M119.40N/AN/A$2.42 per share5.54
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$7M265.50N/AN/A$12.10 per share1.75
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$347.68M5.35N/AN/A$7.64 per share4.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
-$151.09M-$1.81N/AN/AN/AN/A-52.13%-38.01%8/12/2025 (Estimated)
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$274.48M-$3.59N/AN/AN/AN/A-26.74%-25.54%8/5/2025 (Estimated)
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/A0.00N/AN/AN/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-59.76%-32.69%-25.25%8/1/2025 (Estimated)

Latest PFNX, CNTA, IDYA, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
-$0.35-$0.20+$0.15-$0.20N/AN/A
5/6/2025Q1 2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A
5/5/2025Q2 2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
3/24/2025Q4 2024
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
-$0.38-$0.34+$0.04-$0.84N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/AN/AN/AN/AN/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
0.15
21.52
21.52
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/A
14.97
22.93
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
0.03
4.96
4.62

Institutional Ownership

CompanyInstitutional Ownership
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
82.01%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
98.29%
Pfenex Inc. stock logo
PFNX
Pfenex
N/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
7.09%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.50%
Pfenex Inc. stock logo
PFNX
Pfenex
N/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Centessa Pharmaceuticals plc stock logo
CNTA
Centessa Pharmaceuticals
200133.56 million116.56 millionOptionable
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
8087.58 million84.47 millionOptionable
Pfenex Inc. stock logo
PFNX
Pfenex
7134.30 millionN/ANot Optionable
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
99059.92 million57.86 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Centessa Pharmaceuticals stock logo

Centessa Pharmaceuticals NASDAQ:CNTA

$13.41 -0.10 (-0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$13.40 -0.01 (-0.04%)
As of 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

IDEAYA Biosciences stock logo

IDEAYA Biosciences NASDAQ:IDYA

$21.22 +1.33 (+6.69%)
Closing price 04:00 PM Eastern
Extended Trading
$20.50 -0.72 (-3.39%)
As of 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Pfenex stock logo

Pfenex NYSEAMERICAN:PFNX

$12.75 0.00 (0.00%)
As of 10/1/2020

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$31.07 +1.77 (+6.04%)
Closing price 04:00 PM Eastern
Extended Trading
$31.42 +0.34 (+1.11%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.